Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties

Plum, J; Hermann, Swetlana; Fußhöller, Andreas; Schoenicke, Gerrit; Donner, Andreas; Rohrborn, Ansgar; Grabensee, B

doi:10.1046/j.1523-1755.2001.07801.x

Cited by 55 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peritoneal membrane thickening and sclerosis occur commonly in patients on PD [10]; however, it is not clear whether simple sclerosis and EPS represent distinct pathological entities or a spectrum of severity of the same disease process [11]. The principal histological feature of simple sclerosis is increased peritoneal membrane thickness, which is already present in uraemic patients at the start of dialysis [12], increases progressively with time on PD, is more prominent in patients with impaired ultrafiltration capacity and is associated with reduction in arteriolar and venular lumen/vessel diameter ratio.…”

Section: Pathology and Pathogenesismentioning

confidence: 99%

Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications

Augustine

Brown²,

Davies

et al. 2009

Nephron Clin Pract

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis (PD). This review discusses the current understanding of the aetiology and pathogenesis of EPS, highlighting histological features which differentiate it from simple sclerosis of the peritoneal membrane which develops with time on PD. Diagnostic criteria are presented, including the role of imaging techniques. To date there are no randomised controlled trials to guide therapy; however, surgical techniques are an important treatment option. Collaborative research will be essential if this serious problem facing PD is to be solved.

show abstract

Section: Pathology and Pathogenesismentioning

confidence: 99%

Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications

Augustine

Brown²,

Davies

et al. 2009

Nephron Clin Pract

View full text Add to dashboard Cite

show abstract

“…However, after mesothelial cells are always exposed to high glucose dialysate, we examined the activity and expression of p38 MAPK memlong-term treatment with CAPD, peritoneal fibrosis has bers in cultured human peritoneal mesothelial cells (HPMCs) been observed in some patients, resulting in membrane under high glucose conditions. failure [1][2][3]. In vitro and in vivo studies have demon-Methods.…”

Section: Continuous Ambulatory Peritoneal Dialysis (Capd)mentioning

confidence: 99%

High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells

Kim

Park

et al. 2003

Kidney International

View full text Add to dashboard Cite

show abstract

“…However, after long-term treatment with continuous ambulatory PD, peritoneal fibrosis has been observed in some patients, resulting in membrane failure [1]. In vitro and in vivo studies have demonstrated that denudation of mesothelial cells from the peritoneum and excessive deposition of extracellular matrix (ECM) are the structural determinants of peritoneal fibrosis [1,2]. Recurrent peritonitis, bioincompatible PD solution, and high glucose in dialysate per se have been implicated as major factors in the pathogenesis of peritoneal fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Genistein Attenuates Advanced Glycation End Product-Induced Expression of Fibronectin and Connective Tissue Growth Factor

Tong

Wang²,

Wang³

et al. 2012

Am J Nephrol

View full text Add to dashboard Cite

Objective: To investigate the effect of advanced glycation end products (AGEs) on the expression of connective tissue growth factor (CTGF) and fibronectin (FN) in human peritoneal mesothelial cells (HPMC). To observe the effect of genistein (Gen) on the expression of CTGF and FN in HPMC induced by AGEs. Methods: First, HPMC were stimulated with different concentrations of AGEs (0, 200, 600 and 1,000 mg/l) for 48 h; the expression of FN was detected by reverse transcription-polymerase chain reaction (RT-PCR). Second, HPMC were divided into the following groups: (1) control group, (2) AGE-treated group (600 mg/l AGEs) and (3) Gen-treated groups with 600 mg/l AGEs and 25, 50 and 100 µMGen, respectively. The expression of messenger RNA (mRNA) for FN and CTGF was measured by RT-PCR; the expression of FN and CTGF protein was detected by enzyme-linked immunosorbent assay (ELISA) after 48 h. Results: The expression of FN mRNA in HPMC increased in a dose-dependent manner after induction with AGEs. Compared with controls, 600 mg/l AGEs markedly promoted the expression of mRNA and protein for FN and CTGF. Compared with the AGE-treated group (600 mg/l), 25, 50, and 100 µM Gen significantly inhibited the expression of mRNA and protein for FN and CTGF. Conclusion: AGEs can markedly increase the expression of mRNA and protein for FN and CTGF; however, Gen can inhibit the expression of FN and CTGF mRNA and protein stimulated by AGEs, which implies that Gen probably decreases the accumulation of extracellular matrix through inhibiting the expression of CTGF, and it may play a role in anti-peritoneal fibrosis.

show abstract

Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties

Cited by 55 publications

References 0 publications

Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications

Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications

High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells

Genistein Attenuates Advanced Glycation End Product-Induced Expression of Fibronectin and Connective Tissue Growth Factor

Contact Info

Product

Resources

About